CHAMPIONS ONCOLOGY, INC. (CSBR)
As-reported financials and SEC filings for CHAMPIONS ONCOLOGY, INC. The latest annual period is FY2026. The latest reported quarter is Q4 FY2026. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.
About CHAMPIONS ONCOLOGY, INC.
Champions Oncology, Inc. is a research organization that develops technology solutions to support drug discovery and development in oncology. The company operates a large bank of Patient Derived Xenograft (PDX) tumor models used in in vivo and ex vivo pharmacology studies, and offers research services, data licenses, and software tools to pharmaceutical and biotechnology companies and cancer researchers. It also engages in drug discovery and development focused on targeted therapy, immune oncology, and cell therapy.
Snapshot
Fundamentals are from SEC filings for FY2026, the latest annual period (ended April 30, 2026). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.
What changed at Champions Oncology
- Revenue grew 4.4% to $59M in FY2026, slower than the 13.5% the year before.
- Operating margin is now a 1.9% loss in FY2026, from 1.2% in FY2022.
- Most recent quarter Q4 FY2026: revenue $14M, up 12.0% from Q4 FY2025.
- Free cash flow was negative $5M in FY2026.
- Net income turned to a $1M loss in FY2026, from a $5M profit in FY2025.
Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.
Peer comparison
Where Champions Oncology’s fundamentals sit among the 71 biotech companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).
Champions Oncology’s gross margin of 48.0% is the lowest of the 14 biotech companies reporting it.
No reported insider transactions (codes P/S) in the last 90 days. For context, about 15% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →
Percentiles describe where a figure sits among industry peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.
Institutional ownership
Held by 2 quant / multi-strat books among the superinvestors we track; no conviction manager currently reports a position.
| Investor | As of | Position value | Shares | Change |
|---|---|---|---|---|
| Renaissance Technologiesquant | Q2 2026 | $856,480 | 139.0K | Reduced |
| Citadel Advisorsquant | Q2 2026 | $112,697 | 18.3K | New |
From quarterly Form 13F filings, which can be up to 45 days delayed. Long US-listed positions only: excludes short positions, options, cash, bonds, and non-US holdings, so this is not a manager’s complete portfolio. Counts are of the investors we track, not all institutions. Not investment advice.
Short interest
Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 2026-08-14 | 74.0K | -2.8% | 5.97 |
| 2026-07-31 | 76.2K | +0.8% | 9.00 |
| 2026-07-15 | 75.6K | -1.8% | 7.85 |
| 2026-06-30 | 76.9K | -2.1% | 10.45 |
| 2026-06-15 | 78.5K | -2.6% | 12.58 |
| 2026-05-29 | 80.6K | -4.9% | 6.58 |
| 2026-05-15 | 84.7K | +1.2% | 7.58 |
| 2026-04-30 | 83.7K | +2.1% | 13.39 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.
Income statement (as reported)
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $59.4M | $56.9M | $50.2M | $53.9M | $49.1M |
| Gross profit | $28.5M | $28.6M | $20.8M | $24.3M | $25.5M |
| Operating income | $-1.1M | $4.6M | $-7.4M | $-5.3M | $607,000 |
| Net income | $-1.2M | $4.7M | $-7.3M | $-5.3M | $548,000 |
| Diluted EPS | $-0.08 | $0.33 | $-0.54 | $-0.39 | $0.04 |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.
Balance sheet (as reported)
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Cash and equivalents | $4.9M | $9.8M | $2.6M | $10.1M | $9.0M |
| Current assets | $19.2M | $22.4M | $13.6M | $19.5M | $19.7M |
| Total assets | $27.0M | $32.3M | $26.1M | $34.3M | $35.4M |
| Current liabilities | $19.9M | $23.9M | $21.5M | $21.7M | $17.5M |
| Long-term debt | — | — | — | — | — |
| Total liabilities | $22.9M | $28.6M | $28.0M | $29.7M | $26.3M |
| Total equity | $4.1M | $3.8M | $-1.9M | $4.6M | $9.1M |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.
Cash flow (as reported)
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Operating cash flow | $-4.5M | $7.4M | $-6.1M | $4.0M | $6.5M |
| Capital expenditure | $564,000 | $389,000 | $836,000 | $2.9M | $2.4M |
| Free cash flow | $-5.0M | $7.0M | $-7.0M | $1.1M | $4.1M |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.
Quarterly trend (as reported)
| Quarter | Revenue | Revenue YoY | Net income | Diluted EPS |
|---|---|---|---|---|
| Q4 FY2026 | $13.8M | 12.0% | $-667,000 | $-0.05 |
| Q3 FY2026 | $16.6M | -2.8% | $-279,000 | $-0.02 |
| Q2 FY2026 | $15.0M | 11.5% | $268,000 | $0.02 |
| Q1 FY2026 | $14.0M | -0.5% | $-436,000 | $-0.03 |
| Q4 FY2025 | $12.4M | -11.8% | $-1.8M | $-0.12 |
| Q3 FY2025 | $17.0M | 41.8% | $4.5M | $0.31 |
| Q2 FY2025 | $13.5M | 16.6% | $728,000 | $0.05 |
| Q1 FY2025 | $14.1M | 11.9% | $1.3M | $0.09 |
Latest 8 reported quarters, from company XBRL filings on SEC EDGAR.
Company facts
Selected SEC filings
Largest biotech peers
Monitor CSBR
Get an alert when Champions Oncology files something material, see which superinvestors own it, and ask its filings a question with cited answers.
Monitor CSBR freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.